Cancer Chemotherapy and Pharmacology
Overview
Cancer Chemotherapy and Pharmacology is a peer-reviewed journal that focuses on the latest advancements in the field of cancer treatment and pharmacology. It publishes original research articles, reviews, and clinical studies, covering various aspects of chemotherapy, drug development, pharmacokinetics, and pharmacodynamics. The journal aims to provide valuable insights into the efficacy, safety, and mechanisms of anticancer drugs, fostering the development of novel therapeutic strategies for cancer patients.
Details
Details
Metrics
Metrics
h-index / Ranks: 2180
122
SJR / Ranks: 4687
869
CiteScore / Ranks: 3626
6.20
JIF / Ranks: 3481
3.0
Recent Articles
1.
2.
Alandag C, Ozturk A, Yulak F, Sahin Inan Z, Ozkaraca M, Lacin B, et al.
Cancer Chemother Pharmacol
. 2025 Mar;
95(1):42.
PMID: 40080120
No abstract available.
3.
Heldrup J, Bleyer A, Ramsey L, Schaff L, Bernhardt B, Schwartz S, et al.
Cancer Chemother Pharmacol
. 2025 Mar;
95(1):41.
PMID: 40075030
Purpose: Folinic acid (FA) rescue protocols to counter the adverse effects of high-dose methotrexate (HDMTX) vary widely, and the risk of over-rescue and potential adverse effects of excessive FA (e.g.,...
4.
Liguori C, Magi S, Mandolesi A, Agostini A, Svegliati-Baroni G, Benedetti Cacciaguerra A, et al.
Cancer Chemother Pharmacol
. 2025 Mar;
95(1):40.
PMID: 40072607
In recent years, assessing dihydropyrimidine dehydrogenase (DPD) activity has become crucial for cancer patients undergoing 5-fluorouracil (5FU)-based chemotherapy due to the life-threatening toxicity associated with reduced DPD function. The methods...
5.
Darstein C, Yoon D, Yang Y, Kapoor S, Dasgupta K, Wu S, et al.
Cancer Chemother Pharmacol
. 2025 Feb;
95(1):39.
PMID: 40019625
Background: The original population pharmacokinetics (popPK) model for asciminib in patients with chronic myeloid leukemia in chronic phase (CML-CP) was refined to address drug development needs in support of drug...
6.
Ouerdani A, Valenzuela B, Treijtel N, Haddish-Berhane N, Desphande S, Srinivasan S, et al.
Cancer Chemother Pharmacol
. 2025 Feb;
95(1):38.
PMID: 40019563
Purpose: To evaluate alternative ibrutinib dosing regimens that maintain Bruton's tyrosine kinase (BTK) receptor occupancy over the entire dosing interval for CLL patients using a model-based approach. Methods: Ibrutinib inhibits...
7.
Pagnot L, Granger I, Guitton J, Favier B, Ceraulo A, Faure-Conter C, et al.
Cancer Chemother Pharmacol
. 2025 Feb;
95(1):35.
PMID: 39998657
Purpose: Trametinib, a MEK1/2 inhibitor, has emerged as a promising treatment for pediatric patients with low-grade gliomas (LGG). However, trametinib exhibits significant inter-individual pharmacokinetic (PK) variability, and studies in adults...
8.
Scott S, Farago A, Lai W, Zahurak M, Rudek M, Murray J, et al.
Cancer Chemother Pharmacol
. 2025 Feb;
95(1):37.
PMID: 39998620
Purpose: To determine the, safety, tolerability and recommended phase 2 dosing of the combination of navitoclax, a dual Bcl-2/xL inhibitor, and vistusertib, a TORC1/2 inhibitor. Methods: Patients with advanced solid...
9.
Op t Hoog C, Rieborn A, Moes D, Hendrikx J, van der Heijden M, Franken M, et al.
Cancer Chemother Pharmacol
. 2025 Feb;
95(1):36.
PMID: 39998586
Aim: Enfortumab vedotin is an antibody-drug conjugate (ADC) that has been approved for locally advanced or metastatic urothelial cancer, as monotherapy and in combination with pembrolizumab, and has shown significant...
10.
Hanrath M, Banken E, van den Wildenberg S, van de Kerkhof D, Moes D, Boisdron-Celle M, et al.
Cancer Chemother Pharmacol
. 2025 Feb;
95(1):34.
PMID: 39955449
Purpose: In 20-30% of the patients, fluoropyrimidines (5-FU) based chemotherapy leads to severe toxicity, which is associated with dihydropyridine dehydrogenase (DPD) deficiency. Therefore, DPYD genotyping became standard practice before treatment...